Andon Health Co.Ltd(002432) announced that the net profit in the first quarter is expected to be 14-16 billion yuan, with a year-on-year increase of 3670743% – 4196563%.
Andon Health Co.Ltd(002432) opened the trading today, and then pulled back quickly after breaking the board. With the clearing of “fear of heights funds”, as of press time, Andon Health Co.Ltd(002432) closed the board again, up 10%.
Andon Health Co.Ltd(002432) behind the bright performance forecast, “antigen” has become the keyword.
During the reporting period, ihealth US subsidiary of the company sold ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signed major contracts and orders with customers. The increase in sales revenue of this product has made an important contribution to the company’s performance during the reporting period. The company also disclosed the performance express in 2021: the operating revenue in 2021 was 2.513 billion yuan, a year-on-year increase of 25.11%; The net profit attributable to the parent company was 913 million yuan, a year-on-year increase of 276.87%; The basic earnings per share is 2.01 yuan.
overseas epidemic continues to spread, and Chinese covid-19 antigen manufacturers earn more
As the overseas epidemic continues to spread, Delta and Omicron have repeatedly set off tsunamis, which has busy Chinese workers. More than 70% of Australia’s antigen detection kits come from China Made in China has played an indispensable role in the world.
According to the statistics of China’s customs, the export volume of China’s antigen detection related products exceeded 70 billion yuan in 2021. On March 20, the Customs Statistics Platform updated the import and export data of January and February. In the first two months, the export value of China’s covid-19 reagent reached 32.6 billion yuan, and the vast majority of covid-19 reagents exported by China are still antigen detection reagents. China’s covid-19 anti originators received orders and made a lot of money.
At the same time, as the inflection point of China’s epidemic is approaching, “going to sea” means greater market increment. This covid-19 testing enterprise has achieved a “bumper harvest” in the overseas market, which also verifies the view.
Many Chinese enterprises have rapidly developed products for overseas markets. Taking Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) as an example, the company’s covid-19 antigen detection kit (professional version) obtained the EU CE certification in November 2020. In the first half of 2021, the epidemic situation occurred repeatedly in Germany, Britain, India, Brazil and other countries, driving the company’s covid-19 antigen detection reagent sales to increase significantly in that year.
for the “fat meat” of antigen detection, A-share company is eager to try
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) 4 on April 11, the company said on the investor interaction platform that the production capacity of covid-19 nucleic acid detection reagent of the company exceeded 5 million people / day; Covid-19 antigen detection reagent has a production capacity of more than 3 million people / day. The company can expand or shrink the production capacity at any time according to the order demand to meet the changes of market demand.
Shenzhen Yhlo Biotech Co.Ltd(688575) 3 on March 28, the company said on the investor interaction platform that on the basis of strictly implementing the government’s prevention and control policies, the company ensured relevant production and operation and helped with epidemic prevention and control. The New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold method) has obtained the certificate of registration issued by China’s drug administration.
Beijing Hotgen Biotech Co.Ltd(688068) 3 on March 25, we said on the investor interaction platform that the company’s application for FDA certification of covid-19 antigen self-test products is progressing in an orderly manner. When the relevant approval progress meets the conditions for information disclosure, we will disclose the information in time. Please pay attention to the relevant announcements issued by the company in the future.
The biggest year-on-year increase in the performance forecast in 2021 Beijing Hotgen Biotech Co.Ltd(688068) is to seize the opportunity of the rebound of the epidemic in foreign countries. The relevant covid-19 detection reagent products have been certified in many foreign countries and regions, and the foreign trade orders have surged, which promotes the substantial growth of the company’s operating performance in 2021.
